JP2013540119A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013540119A5 JP2013540119A5 JP2013530829A JP2013530829A JP2013540119A5 JP 2013540119 A5 JP2013540119 A5 JP 2013540119A5 JP 2013530829 A JP2013530829 A JP 2013530829A JP 2013530829 A JP2013530829 A JP 2013530829A JP 2013540119 A5 JP2013540119 A5 JP 2013540119A5
- Authority
- JP
- Japan
- Prior art keywords
- oxo
- carbonyl
- spiro
- tetrahydro
- benzoic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 hydroxy, fluoro, phenyl Chemical group 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 9
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 239000005711 Benzoic acid Substances 0.000 claims 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 3
- 235000010233 benzoic acid Nutrition 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000001041 indolyl group Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims 3
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- CROBEOGUJFDYPA-UHFFFAOYSA-N 3-[2-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)-1h-benzimidazol-4-yl]benzoic acid Chemical compound C1C(=O)C=2N(C(C)C)N=CC=2CC1(CC1)CCN1C(=O)C(NC1=CC=C2)=NC1=C2C1=CC=CC(C(O)=O)=C1 CROBEOGUJFDYPA-UHFFFAOYSA-N 0.000 claims 2
- HATGWLFXYOJZDJ-UHFFFAOYSA-N 3-[2-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)-1h-indol-4-yl]benzoic acid Chemical compound C1C(=O)C=2N(C(C)C)N=CC=2CC1(CC1)CCN1C(=O)C(NC1=CC=C2)=CC1=C2C1=CC=CC(C(O)=O)=C1 HATGWLFXYOJZDJ-UHFFFAOYSA-N 0.000 claims 2
- CGPLWVIRHVCYDM-UHFFFAOYSA-N 3-[2-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)-1h-pyrrolo[2,3-b]pyridin-4-yl]benzoic acid Chemical compound C1C(=O)C=2N(C(C)C)N=CC=2CC1(CC1)CCN1C(=O)C(NC1=NC=C2)=CC1=C2C1=CC=CC(C(O)=O)=C1 CGPLWVIRHVCYDM-UHFFFAOYSA-N 0.000 claims 2
- HXEJBKSDELCRJK-UHFFFAOYSA-N 3-[6-methoxy-4-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)pyridin-2-yl]benzoic acid Chemical compound N=1C(OC)=CC(C(=O)N2CCC3(CC2)CC(=O)C=2N(C(C)C)N=CC=2C3)=CC=1C1=CC=CC(C(O)=O)=C1 HXEJBKSDELCRJK-UHFFFAOYSA-N 0.000 claims 2
- REPTXPNSUUKFMQ-UHFFFAOYSA-N 3-[6-oxo-4-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)-1h-pyridin-2-yl]benzoic acid Chemical compound C1C(=O)C=2N(C(C)C)N=CC=2CC1(CC1)CCN1C(=O)C(=CC(=O)N1)C=C1C1=CC=CC(C(O)=O)=C1 REPTXPNSUUKFMQ-UHFFFAOYSA-N 0.000 claims 2
- NMUDXSTWPJFVCN-UHFFFAOYSA-N 4-[6-(dimethylamino)-4-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)pyridin-2-yl]benzoic acid Chemical compound C1C(=O)C=2N(C(C)C)N=CC=2CC1(CC1)CCN1C(=O)C(C=1)=CC(N(C)C)=NC=1C1=CC=C(C(O)=O)C=C1 NMUDXSTWPJFVCN-UHFFFAOYSA-N 0.000 claims 2
- PSBXMLBCZHXXRZ-UHFFFAOYSA-N 4-[[4-(1-tert-butyl-7-oxospiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)phenoxy]methyl]benzoic acid Chemical compound C1C(=O)C=2N(C(C)(C)C)N=CC=2CC1(CC1)CCN1C(=O)C(C=C1)=CC=C1OCC1=CC=C(C(O)=O)C=C1 PSBXMLBCZHXXRZ-UHFFFAOYSA-N 0.000 claims 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 229940125708 antidiabetic agent Drugs 0.000 claims 2
- 239000003472 antidiabetic agent Substances 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 229960004580 glibenclamide Drugs 0.000 claims 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 claims 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 125000003566 oxetanyl group Chemical group 0.000 claims 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims 1
- FOZFSEMFCIPOSZ-SPCKQMHLSA-N (2r,3r,4r,5s)-2-(hydroxymethyl)-1-[[(2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-methoxyoxan-2-yl]methyl]piperidine-3,4,5-triol;trihydrate Chemical compound O.O.O.O[C@H]1[C@H](O)[C@@H](O)[C@@H](OC)O[C@@H]1CN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1.O[C@H]1[C@H](O)[C@@H](O)[C@@H](OC)O[C@@H]1CN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1 FOZFSEMFCIPOSZ-SPCKQMHLSA-N 0.000 claims 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 claims 1
- GQPZAWWEJRPKBC-UHFFFAOYSA-N 1-propan-2-yl-1'-[4-[3-(2h-tetrazol-5-yl)phenyl]benzoyl]spiro[4,6-dihydroindazole-5,4'-piperidine]-7-one Chemical compound C1C(=O)C=2N(C(C)C)N=CC=2CC1(CC1)CCN1C(=O)C(C=C1)=CC=C1C(C=1)=CC=CC=1C1=NN=NN1 GQPZAWWEJRPKBC-UHFFFAOYSA-N 0.000 claims 1
- VCQDLEYFWQYIRF-UHFFFAOYSA-N 1-tert-butyl-1'-[4-[3-(2h-tetrazol-5-yl)phenyl]benzoyl]spiro[4,6-dihydroindazole-5,4'-piperidine]-7-one Chemical compound C1C(=O)C=2N(C(C)(C)C)N=CC=2CC1(CC1)CCN1C(=O)C(C=C1)=CC=C1C(C=1)=CC=CC=1C1=NN=NN1 VCQDLEYFWQYIRF-UHFFFAOYSA-N 0.000 claims 1
- SQGNBGAYPGECDT-UHFFFAOYSA-N 2-[2-methoxy-5-[2-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)-1h-indol-4-yl]phenyl]acetic acid Chemical compound C1=C(CC(O)=O)C(OC)=CC=C1C1=CC=CC2=C1C=C(C(=O)N1CCC3(CC1)CC(=O)C=1N(C(C)C)N=CC=1C3)N2 SQGNBGAYPGECDT-UHFFFAOYSA-N 0.000 claims 1
- DIEOLUPIWBVGPD-UHFFFAOYSA-N 3-(1,3-oxazol-2-yl)-5-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)benzoic acid Chemical compound C1C(=O)C=2N(C(C)C)N=CC=2CC1(CC1)CCN1C(=O)C(C=1)=CC(C(O)=O)=CC=1C1=NC=CO1 DIEOLUPIWBVGPD-UHFFFAOYSA-N 0.000 claims 1
- CUPARKJNRPBOAC-UHFFFAOYSA-N 3-(1-tert-butyl-7-oxospiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)-5-(1,3-oxazol-2-yl)benzoic acid Chemical compound C1C(=O)C=2N(C(C)(C)C)N=CC=2CC1(CC1)CCN1C(=O)C(C=1)=CC(C(O)=O)=CC=1C1=NC=CO1 CUPARKJNRPBOAC-UHFFFAOYSA-N 0.000 claims 1
- LHHYGFACCLSIRS-UHFFFAOYSA-N 3-[2-(1-tert-butyl-7-oxospiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)-1h-indol-4-yl]benzoic acid Chemical compound C1C(=O)C=2N(C(C)(C)C)N=CC=2CC1(CC1)CCN1C(=O)C(NC1=CC=C2)=CC1=C2C1=CC=CC(C(O)=O)=C1 LHHYGFACCLSIRS-UHFFFAOYSA-N 0.000 claims 1
- FRIOVTCXANEONN-UHFFFAOYSA-N 3-[2-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)-1h-indol-6-yl]benzoic acid Chemical compound C1C(=O)C=2N(C(C)C)N=CC=2CC1(CC1)CCN1C(=O)C(NC1=C2)=CC1=CC=C2C1=CC=CC(C(O)=O)=C1 FRIOVTCXANEONN-UHFFFAOYSA-N 0.000 claims 1
- WECUJSSWTZPGDL-UHFFFAOYSA-N 3-[2-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)-1h-pyrrolo[2,3-c]pyridin-4-yl]benzoic acid Chemical compound C1C(=O)C=2N(C(C)C)N=CC=2CC1(CC1)CCN1C(=O)C(NC1=CN=C2)=CC1=C2C1=CC=CC(C(O)=O)=C1 WECUJSSWTZPGDL-UHFFFAOYSA-N 0.000 claims 1
- OYTBONCRVYVFRS-UHFFFAOYSA-N 3-[2-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)-1h-pyrrolo[3,2-c]pyridin-4-yl]benzoic acid Chemical compound C1C(=O)C=2N(C(C)C)N=CC=2CC1(CC1)CCN1C(=O)C(NC1=CC=N2)=CC1=C2C1=CC=CC(C(O)=O)=C1 OYTBONCRVYVFRS-UHFFFAOYSA-N 0.000 claims 1
- GFGJQKQIDINRPX-UHFFFAOYSA-N 3-[2-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)-3h-benzimidazol-5-yl]benzoic acid Chemical compound C1C(=O)C=2N(C(C)C)N=CC=2CC1(CC1)CCN1C(=O)C(NC1=CC=2)=NC1=CC=2C1=CC=CC(C(O)=O)=C1 GFGJQKQIDINRPX-UHFFFAOYSA-N 0.000 claims 1
- KMDKGZWGKLAZSW-UHFFFAOYSA-N 3-[4-(1-tert-butyl-7-oxospiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl]benzoic acid Chemical compound N=1C(OC)=CC(C(=O)N2CCC3(CC2)CC(=O)C=2N(N=CC=2C3)C(C)(C)C)=CC=1C1=CC=CC(C(O)=O)=C1 KMDKGZWGKLAZSW-UHFFFAOYSA-N 0.000 claims 1
- RUSHODREPMAKFT-UHFFFAOYSA-N 3-[4-(1-tert-butyl-7-oxospiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)phenyl]benzoic acid Chemical compound C1C(=O)C=2N(C(C)(C)C)N=CC=2CC1(CC1)CCN1C(=O)C(C=C1)=CC=C1C1=CC=CC(C(O)=O)=C1 RUSHODREPMAKFT-UHFFFAOYSA-N 0.000 claims 1
- GZOSFBCGVXPKAL-UHFFFAOYSA-N 3-[4-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)phenyl]benzoic acid Chemical compound C1C(=O)C=2N(C(C)C)N=CC=2CC1(CC1)CCN1C(=O)C(C=C1)=CC=C1C1=CC=CC(C(O)=O)=C1 GZOSFBCGVXPKAL-UHFFFAOYSA-N 0.000 claims 1
- NQFXZBLVPWGBEQ-UHFFFAOYSA-N 3-[5-(1-tert-butyl-7-oxospiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)-6-(ethylamino)pyridin-2-yl]benzoic acid Chemical compound C=1C=C(C(=O)N2CCC3(CC2)CC(=O)C=2N(N=CC=2C3)C(C)(C)C)C(NCC)=NC=1C1=CC=CC(C(O)=O)=C1 NQFXZBLVPWGBEQ-UHFFFAOYSA-N 0.000 claims 1
- ASMSFMZFSITJMS-UHFFFAOYSA-N 3-[5-(1-tert-butyl-7-oxospiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)-6-(methylamino)pyridin-2-yl]benzoic acid Chemical compound C=1C=C(C(=O)N2CCC3(CC2)CC(=O)C=2N(N=CC=2C3)C(C)(C)C)C(NC)=NC=1C1=CC=CC(C(O)=O)=C1 ASMSFMZFSITJMS-UHFFFAOYSA-N 0.000 claims 1
- MRDCPTCBCJUGJZ-UHFFFAOYSA-N 3-[5-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)-6-(propan-2-ylamino)pyridin-2-yl]benzoic acid Chemical compound C=1C=C(C(=O)N2CCC3(CC2)CC(=O)C=2N(C(C)C)N=CC=2C3)C(NC(C)C)=NC=1C1=CC=CC(C(O)=O)=C1 MRDCPTCBCJUGJZ-UHFFFAOYSA-N 0.000 claims 1
- HTSATYCBQUXNDH-UHFFFAOYSA-N 3-[6-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)-1h-indol-4-yl]benzoic acid Chemical compound C1C(=O)C=2N(C(C)C)N=CC=2CC1(CC1)CCN1C(=O)C(C=C1NC=CC1=1)=CC=1C1=CC=CC(C(O)=O)=C1 HTSATYCBQUXNDH-UHFFFAOYSA-N 0.000 claims 1
- DXAYBSGJUCJQIV-UHFFFAOYSA-N 3-[6-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]benzoic acid Chemical compound C1C(=O)C=2N(C(C)C)N=CC=2CC1(CC1)CCN1C(=O)C(NC1=NC=N2)=CC1=C2C1=CC=CC(C(O)=O)=C1 DXAYBSGJUCJQIV-UHFFFAOYSA-N 0.000 claims 1
- OWCFADICMXYNHA-UHFFFAOYSA-N 3-[6-(dimethylamino)-4-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)pyridin-2-yl]benzoic acid Chemical compound C1C(=O)C=2N(C(C)C)N=CC=2CC1(CC1)CCN1C(=O)C(C=1)=CC(N(C)C)=NC=1C1=CC=CC(C(O)=O)=C1 OWCFADICMXYNHA-UHFFFAOYSA-N 0.000 claims 1
- VOXNMQIQGVOHTP-UHFFFAOYSA-N 3-[6-(ethylamino)-5-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)pyridin-2-yl]benzoic acid Chemical compound C=1C=C(C(=O)N2CCC3(CC2)CC(=O)C=2N(C(C)C)N=CC=2C3)C(NCC)=NC=1C1=CC=CC(C(O)=O)=C1 VOXNMQIQGVOHTP-UHFFFAOYSA-N 0.000 claims 1
- KHNSXXJIOZMVSR-UHFFFAOYSA-N 3-[6-(methylamino)-5-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)pyridin-2-yl]benzoic acid Chemical compound C=1C=C(C(=O)N2CCC3(CC2)CC(=O)C=2N(C(C)C)N=CC=2C3)C(NC)=NC=1C1=CC=CC(C(O)=O)=C1 KHNSXXJIOZMVSR-UHFFFAOYSA-N 0.000 claims 1
- VVRKTWHMLVQLSX-UHFFFAOYSA-N 3-[6-(methylamino)-5-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)pyridin-3-yl]benzoic acid Chemical compound C1=C(C(=O)N2CCC3(CC2)CC(=O)C=2N(C(C)C)N=CC=2C3)C(NC)=NC=C1C1=CC=CC(C(O)=O)=C1 VVRKTWHMLVQLSX-UHFFFAOYSA-N 0.000 claims 1
- LMLWDHXQEFSYIS-UHFFFAOYSA-N 4-[2-(1-tert-butyl-7-oxospiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)-1h-indol-4-yl]benzoic acid Chemical compound C1C(=O)C=2N(C(C)(C)C)N=CC=2CC1(CC1)CCN1C(=O)C(NC1=CC=C2)=CC1=C2C1=CC=C(C(O)=O)C=C1 LMLWDHXQEFSYIS-UHFFFAOYSA-N 0.000 claims 1
- CJXBPTFRHOUSQA-UHFFFAOYSA-N 4-[2-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)-1h-indol-4-yl]benzoic acid Chemical compound C1C(=O)C=2N(C(C)C)N=CC=2CC1(CC1)CCN1C(=O)C(NC1=CC=C2)=CC1=C2C1=CC=C(C(O)=O)C=C1 CJXBPTFRHOUSQA-UHFFFAOYSA-N 0.000 claims 1
- VKIQXEPHWQUFNJ-UHFFFAOYSA-N 4-[2-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)-1h-pyrrolo[2,3-b]pyridin-4-yl]benzoic acid Chemical compound C1C(=O)C=2N(C(C)C)N=CC=2CC1(CC1)CCN1C(=O)C(NC1=NC=C2)=CC1=C2C1=CC=C(C(O)=O)C=C1 VKIQXEPHWQUFNJ-UHFFFAOYSA-N 0.000 claims 1
- OIKUWZYIYYRWSF-UHFFFAOYSA-N 4-[2-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)-1h-pyrrolo[2,3-c]pyridin-4-yl]benzoic acid Chemical compound C1C(=O)C=2N(C(C)C)N=CC=2CC1(CC1)CCN1C(=O)C(NC1=CN=C2)=CC1=C2C1=CC=C(C(O)=O)C=C1 OIKUWZYIYYRWSF-UHFFFAOYSA-N 0.000 claims 1
- OSZRMXOUTAIXDP-UHFFFAOYSA-N 4-[2-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)-1h-pyrrolo[3,2-c]pyridin-4-yl]benzoic acid Chemical compound C1C(=O)C=2N(C(C)C)N=CC=2CC1(CC1)CCN1C(=O)C(NC1=CC=N2)=CC1=C2C1=CC=C(C(O)=O)C=C1 OSZRMXOUTAIXDP-UHFFFAOYSA-N 0.000 claims 1
- TXFRLVBIQLXQJL-UHFFFAOYSA-N 4-[2-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)-3h-benzimidazol-5-yl]benzoic acid Chemical compound C1C(=O)C=2N(C(C)C)N=CC=2CC1(CC1)CCN1C(=O)C(NC1=CC=2)=NC1=CC=2C1=CC=C(C(O)=O)C=C1 TXFRLVBIQLXQJL-UHFFFAOYSA-N 0.000 claims 1
- RQLXQJYCJYDSOW-UHFFFAOYSA-N 4-[4-(1-tert-butyl-7-oxospiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl]benzoic acid Chemical compound N=1C(OC)=CC(C(=O)N2CCC3(CC2)CC(=O)C=2N(N=CC=2C3)C(C)(C)C)=CC=1C1=CC=C(C(O)=O)C=C1 RQLXQJYCJYDSOW-UHFFFAOYSA-N 0.000 claims 1
- FGIKRLQXMGNCRG-UHFFFAOYSA-N 4-[5-(1-tert-butyl-7-oxospiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)-6-(ethylamino)pyridin-2-yl]benzoic acid Chemical compound C=1C=C(C(=O)N2CCC3(CC2)CC(=O)C=2N(N=CC=2C3)C(C)(C)C)C(NCC)=NC=1C1=CC=C(C(O)=O)C=C1 FGIKRLQXMGNCRG-UHFFFAOYSA-N 0.000 claims 1
- RBTJJDHOAMTQLN-UHFFFAOYSA-N 4-[5-(1-tert-butyl-7-oxospiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)-6-(methylamino)pyridin-2-yl]benzoic acid Chemical compound C=1C=C(C(=O)N2CCC3(CC2)CC(=O)C=2N(N=CC=2C3)C(C)(C)C)C(NC)=NC=1C1=CC=C(C(O)=O)C=C1 RBTJJDHOAMTQLN-UHFFFAOYSA-N 0.000 claims 1
- KKFYTKHPLCTUSR-UHFFFAOYSA-N 4-[5-(1-tert-butyl-7-oxospiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)-6-(propan-2-ylamino)pyridin-2-yl]benzoic acid Chemical compound C=1C=C(C(=O)N2CCC3(CC2)CC(=O)C=2N(N=CC=2C3)C(C)(C)C)C(NC(C)C)=NC=1C1=CC=C(C(O)=O)C=C1 KKFYTKHPLCTUSR-UHFFFAOYSA-N 0.000 claims 1
- BMAWWSNROOOAHU-UHFFFAOYSA-N 4-[5-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)-6-(2,2,2-trifluoroethylamino)pyridin-2-yl]benzoic acid Chemical compound C1C(=O)C=2N(C(C)C)N=CC=2CC1(CC1)CCN1C(=O)C(C(=N1)NCC(F)(F)F)=CC=C1C1=CC=C(C(O)=O)C=C1 BMAWWSNROOOAHU-UHFFFAOYSA-N 0.000 claims 1
- SQUIHSWHMNRFSB-UHFFFAOYSA-N 4-[5-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)-6-(propan-2-ylamino)pyridin-2-yl]benzoic acid Chemical compound C=1C=C(C(=O)N2CCC3(CC2)CC(=O)C=2N(C(C)C)N=CC=2C3)C(NC(C)C)=NC=1C1=CC=C(C(O)=O)C=C1 SQUIHSWHMNRFSB-UHFFFAOYSA-N 0.000 claims 1
- GYDFQCNEWIQGBU-UHFFFAOYSA-N 4-[6-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)-1h-indazol-4-yl]benzoic acid Chemical compound C1C(=O)C=2N(C(C)C)N=CC=2CC1(CC1)CCN1C(=O)C(C=C1NN=CC1=1)=CC=1C1=CC=C(C(O)=O)C=C1 GYDFQCNEWIQGBU-UHFFFAOYSA-N 0.000 claims 1
- AJXVARJRUZAGGU-UHFFFAOYSA-N 4-[6-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)-1h-indol-4-yl]benzoic acid Chemical compound C1C(=O)C=2N(C(C)C)N=CC=2CC1(CC1)CCN1C(=O)C(C=C1NC=CC1=1)=CC=1C1=CC=C(C(O)=O)C=C1 AJXVARJRUZAGGU-UHFFFAOYSA-N 0.000 claims 1
- VEZSJHGKCLHKGI-UHFFFAOYSA-N 4-[6-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]benzoic acid Chemical compound C1C(=O)C=2N(C(C)C)N=CC=2CC1(CC1)CCN1C(=O)C(NC1=NC=N2)=CC1=C2C1=CC=C(C(O)=O)C=C1 VEZSJHGKCLHKGI-UHFFFAOYSA-N 0.000 claims 1
- MATBUMXHNJSSGA-UHFFFAOYSA-N 4-[6-(ethylamino)-5-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)pyridin-2-yl]benzoic acid Chemical compound C=1C=C(C(=O)N2CCC3(CC2)CC(=O)C=2N(C(C)C)N=CC=2C3)C(NCC)=NC=1C1=CC=C(C(O)=O)C=C1 MATBUMXHNJSSGA-UHFFFAOYSA-N 0.000 claims 1
- ABKRQUWBBYVPFN-UHFFFAOYSA-N 4-[6-(methylamino)-5-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)pyridin-2-yl]benzoic acid Chemical compound C=1C=C(C(=O)N2CCC3(CC2)CC(=O)C=2N(C(C)C)N=CC=2C3)C(NC)=NC=1C1=CC=C(C(O)=O)C=C1 ABKRQUWBBYVPFN-UHFFFAOYSA-N 0.000 claims 1
- CVRQVFOADVHKRG-UHFFFAOYSA-N 4-[6-(methylamino)-5-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)pyridin-3-yl]benzoic acid Chemical compound C1=C(C(=O)N2CCC3(CC2)CC(=O)C=2N(C(C)C)N=CC=2C3)C(NC)=NC=C1C1=CC=C(C(O)=O)C=C1 CVRQVFOADVHKRG-UHFFFAOYSA-N 0.000 claims 1
- LXZMHBHEXAELHH-UHFFFAOYSA-N 4-[6-methoxy-4-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)pyridin-2-yl]benzoic acid Chemical compound N=1C(OC)=CC(C(=O)N2CCC3(CC2)CC(=O)C=2N(C(C)C)N=CC=2C3)=CC=1C1=CC=C(C(O)=O)C=C1 LXZMHBHEXAELHH-UHFFFAOYSA-N 0.000 claims 1
- BPBHPVGUABASSC-UHFFFAOYSA-N 4-[6-oxo-4-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)-1h-pyridin-2-yl]benzoic acid Chemical compound C1C(=O)C=2N(C(C)C)N=CC=2CC1(CC1)CCN1C(=O)C(=CC(=O)N1)C=C1C1=CC=C(C(O)=O)C=C1 BPBHPVGUABASSC-UHFFFAOYSA-N 0.000 claims 1
- MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 claims 1
- 108010011459 Exenatide Proteins 0.000 claims 1
- 102000016267 Leptin Human genes 0.000 claims 1
- 108010092277 Leptin Proteins 0.000 claims 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 claims 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 claims 1
- 229930186167 Trestatin Natural products 0.000 claims 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 claims 1
- 229960002632 acarbose Drugs 0.000 claims 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims 1
- 229960001466 acetohexamide Drugs 0.000 claims 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 229950001261 camiglibose Drugs 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 claims 1
- 229960001761 chlorpropamide Drugs 0.000 claims 1
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 claims 1
- 229950009226 ciglitazone Drugs 0.000 claims 1
- QQKNSPHAFATFNQ-UHFFFAOYSA-N darglitazone Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCC(=O)C(C=C1)=CC=C1CC1SC(=O)NC1=O QQKNSPHAFATFNQ-UHFFFAOYSA-N 0.000 claims 1
- 229950006689 darglitazone Drugs 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 claims 1
- 229950000269 emiglitate Drugs 0.000 claims 1
- 229950002375 englitazone Drugs 0.000 claims 1
- NWWORXYTJRPSMC-QKPAOTATSA-N ethyl 4-[2-[(2r,3r,4r,5s)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]ethoxy]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1OCCN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1 NWWORXYTJRPSMC-QKPAOTATSA-N 0.000 claims 1
- 229960001519 exenatide Drugs 0.000 claims 1
- 108010015174 exendin 3 Proteins 0.000 claims 1
- LMHMJYMCGJNXRS-IOPUOMRJSA-N exendin-3 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@H](C)O)[C@H](C)O)C(C)C)C1=CC=CC=C1 LMHMJYMCGJNXRS-IOPUOMRJSA-N 0.000 claims 1
- 229960000346 gliclazide Drugs 0.000 claims 1
- 229960004346 glimepiride Drugs 0.000 claims 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 claims 1
- 229960001381 glipizide Drugs 0.000 claims 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 claims 1
- 229950008402 glisentide Drugs 0.000 claims 1
- NSJYMFYVNWVGON-UHFFFAOYSA-N glisentide Chemical compound COC1=CC=CC=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCC2)C=C1 NSJYMFYVNWVGON-UHFFFAOYSA-N 0.000 claims 1
- 229950005319 glisolamide Drugs 0.000 claims 1
- GZKDXUIWCNCNBJ-UHFFFAOYSA-N glisolamide Chemical compound O1C(C)=CC(C(=O)NCCC=2C=CC(=CC=2)S(=O)(=O)NC(=O)NC2CCCCC2)=N1 GZKDXUIWCNCNBJ-UHFFFAOYSA-N 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 229940039781 leptin Drugs 0.000 claims 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 1
- 229960003105 metformin Drugs 0.000 claims 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical group CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 229960001110 miglitol Drugs 0.000 claims 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims 1
- PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229960005095 pioglitazone Drugs 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 229960004586 rosiglitazone Drugs 0.000 claims 1
- 229960004937 saxagliptin Drugs 0.000 claims 1
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 claims 1
- 108010033693 saxagliptin Proteins 0.000 claims 1
- 229960004034 sitagliptin Drugs 0.000 claims 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 claims 1
- 229950001790 tendamistat Drugs 0.000 claims 1
- 108010037401 tendamistate Proteins 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 229960002277 tolazamide Drugs 0.000 claims 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 claims 1
- 229960005371 tolbutamide Drugs 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims 1
- 229960001641 troglitazone Drugs 0.000 claims 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 claims 1
- 229960001254 vildagliptin Drugs 0.000 claims 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 claims 1
- 229960001729 voglibose Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38810210P | 2010-09-30 | 2010-09-30 | |
| US61/388,102 | 2010-09-30 | ||
| PCT/IB2011/054119 WO2012042433A1 (en) | 2010-09-30 | 2011-09-20 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013540119A JP2013540119A (ja) | 2013-10-31 |
| JP2013540119A5 true JP2013540119A5 (cg-RX-API-DMAC7.html) | 2014-10-16 |
| JP5824055B2 JP5824055B2 (ja) | 2015-11-25 |
Family
ID=44789556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013530829A Active JP5824055B2 (ja) | 2010-09-30 | 2011-09-20 | Ｎ１−ピラゾロスピロケトンアセチル−ＣｏＡカルボキシラーゼ阻害剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (8) | US8859577B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2621493B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5824055B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2811033C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1118016T1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2621493T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2602111T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20161178T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE031616T2 (cg-RX-API-DMAC7.html) |
| LT (1) | LT2621493T (cg-RX-API-DMAC7.html) |
| PL (1) | PL2621493T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2621493T (cg-RX-API-DMAC7.html) |
| RS (1) | RS55224B1 (cg-RX-API-DMAC7.html) |
| SI (1) | SI2621493T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012042433A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040198483A1 (en) | 2003-04-03 | 2004-10-07 | Amaitis Lee M. | System and method for betting on a subset of participants in an event |
| US8636571B2 (en) | 2004-02-03 | 2014-01-28 | Cantor Index, Llc | System and method for managing select five horseracing bets |
| US9098883B2 (en) | 2004-02-03 | 2015-08-04 | Cantor Index, Llc | Managing bets that select events and participants |
| JP5435592B2 (ja) | 2008-05-28 | 2014-03-05 | ファイザー・インク | ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤 |
| ES2444543T3 (es) | 2009-11-10 | 2014-02-25 | Pfizer Inc | Inhibidores de la N1-pirazoloespirocetona acetil-CoA carboxilasa |
| EP2621493B1 (en) | 2010-09-30 | 2016-08-17 | Pfizer Inc | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS |
| CN104774205A (zh) | 2010-10-29 | 2015-07-15 | 辉瑞大药厂 | N1/n2-内酰胺乙酰辅酶a羧化酶抑制剂 |
| JP5657174B2 (ja) * | 2011-04-22 | 2015-01-21 | ファイザー・インク | アセチルＣｏＡカルボキシラーゼ阻害剤として使用するためのピラゾロスピロケトン誘導体 |
| CA2863365A1 (en) | 2012-01-30 | 2013-08-08 | Cfph, Llc | Event wagering with group and/or in run options |
| US11055967B2 (en) | 2014-03-26 | 2021-07-06 | Cfph, Llc | Event wagering with group and/or in run options |
| US20170178994A1 (en) * | 2015-12-21 | 2017-06-22 | Intel Corporation | Integrated circuit package support structures |
| KR102579876B1 (ko) | 2016-02-22 | 2023-09-18 | 삼성전자주식회사 | 반도체 패키지 |
| EP3612175B1 (en) * | 2017-04-18 | 2025-09-10 | Genfit | Combination of elafibranor with an anti-nash, anti-fibrotic or anti-cholestatic agent |
| DK3713942T3 (da) * | 2017-11-21 | 2023-04-03 | Pfizer | Krystallinsk 2-amino-2-(hydroxymethyl)propan-1,3-diol-salt af 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazol-5,4'-piperidin]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoesyre |
| CA3045644C (en) | 2018-06-13 | 2024-01-16 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| CN112955147A (zh) * | 2018-08-31 | 2021-06-11 | 辉瑞公司 | 用于治疗nash/nafld和相关疾病的组合 |
| WO2020234726A1 (en) | 2019-05-20 | 2020-11-26 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
| CN110183456A (zh) * | 2019-07-11 | 2019-08-30 | 河南师范大学 | 一种2-芳基吲唑琥珀酰亚胺螺环化合物的合成方法 |
| KR20220112811A (ko) | 2019-12-10 | 2022-08-11 | 화이자 인코포레이티드 | 2-((4-((S)-2-(5-클로로피리딘-2-일)-2-메틸벤조[d][1,3]디옥솔-4-일)피페리딘-1-일)메틸)-1-(((S)-옥세탄-2-일)메틸)-1H-벤조[d]이미다졸-6-카르복실산, 1,3-디히드록시-2-(히드록시메틸)프로판-2-아민 염의 고체 형태 |
| EP4085056A1 (en) | 2020-01-03 | 2022-11-09 | Berg LLC | Polycyclic amides as ube2k modulators for treating cancer |
| PH12022552056A1 (en) | 2020-02-07 | 2024-02-12 | Gasherbrum Bio Inc | Heterocyclic glp-1 agonists |
| JP2022058085A (ja) | 2020-02-24 | 2022-04-11 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ |
| JP2021134211A (ja) * | 2020-02-24 | 2021-09-13 | ファイザー・インク | Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ |
| BR112022017578A2 (pt) | 2020-03-27 | 2022-10-18 | Pfizer | Tratamento do diabetes tipo 2 ou obesidade ou sobrepeso com ácido 2-[(4-{6-[(4-ciano-2-fluorobenzil)óxi]piridin-2-il}piperidin-1-il)metil]-1-[(2s)-oxetan-2-ilmetil]-1h-benzimidazol-6-carboxílico ou um sal farmacêutico do mesmo |
| EP4396182A1 (en) | 2021-08-31 | 2024-07-10 | Pfizer Inc. | Solid forms of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt |
| JP2025509281A (ja) | 2022-03-09 | 2025-04-11 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環式ｇｌｐ－１アゴニスト |
| WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2023228023A1 (en) | 2022-05-23 | 2023-11-30 | Pfizer Inc. | Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof |
| AU2023364628A1 (en) | 2022-10-18 | 2025-04-03 | Pfizer Inc. | Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers |
| WO2024125602A1 (en) | 2022-12-15 | 2024-06-20 | Gasherbrum Bio, Inc. | Salts and solid forms of a compound having glp-1 agonist activity |
| WO2025099561A1 (en) | 2023-11-07 | 2025-05-15 | Pfizer Inc. | Oral controlled-release matrix formulations of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof |
| WO2025224648A1 (en) | 2024-04-26 | 2025-10-30 | Pfizer Inc. | Oral compositions/formulations of 2-({4-[(2s)-2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0901786B1 (en) | 1997-08-11 | 2007-06-13 | Pfizer Products Inc. | Solid pharmaceutical dispersions with enhanced bioavailability |
| SK286917B6 (sk) | 2001-02-28 | 2009-07-06 | Merck & Co., Inc. | 4-Substituované N-acylované deriváty piperidínu, farmaceutický prípravok s ich obsahom a ich použitie |
| EP1478437B1 (en) | 2002-02-27 | 2005-08-31 | Pfizer Products Inc. | Acc inhibitors |
| US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
| WO2004092179A1 (ja) | 2003-04-14 | 2004-10-28 | Nippon Soda Co. Ltd. | スピロ誘導体、製造法および抗酸化薬 |
| JP2005119987A (ja) | 2003-10-15 | 2005-05-12 | Ajinomoto Co Inc | アシルスルホンアミド誘導体 |
| US20050267221A1 (en) | 2004-05-14 | 2005-12-01 | Research Development Foundation | Use of curcumin and analogues thereof as inhibitors of ACC2 |
| AU2005247693A1 (en) | 2004-05-25 | 2005-12-08 | Pfizer Products Inc. | Tetraazabenzo[E]azulene derivatives and analogs thereof |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| CA2614963C (en) | 2005-07-19 | 2014-10-07 | Merck & Co., Inc. | Spirochromanone derivatives as acetyl coenzyme a carboxylase (acc) inhibitors |
| EP1911753A1 (en) | 2005-07-29 | 2008-04-16 | Takeda Pharmaceutical Company Limited | Spiro-cyclic compound |
| DE102006016566B4 (de) | 2005-09-22 | 2008-06-12 | Beru Ag | Zusammengesetzter Leiter, insbesondere für Glühkerzen für Dieselmotoren |
| JP2009515971A (ja) | 2005-11-18 | 2009-04-16 | メルク エンド カムパニー インコーポレーテッド | スピロヒダントインアリールｃｇｒｐ受容体アンタゴニスト |
| CA2641766A1 (en) | 2006-02-15 | 2007-08-23 | Abbott Laboratories | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome |
| ATE552262T1 (de) | 2006-11-29 | 2012-04-15 | Pfizer Prod Inc | Spiroketone als inhibitoren von acetyl-coa- carboxylase |
| AU2008205642B2 (en) * | 2007-01-12 | 2013-06-06 | Msd K.K. | Spirochromanon derivatives |
| PE20081559A1 (es) | 2007-01-12 | 2008-11-20 | Merck & Co Inc | DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA |
| WO2008102749A1 (ja) * | 2007-02-20 | 2008-08-28 | Takeda Pharmaceutical Company Limited | 複素環化合物 |
| CN101675052A (zh) | 2007-04-12 | 2010-03-17 | 辉瑞大药厂 | 作为蛋白酶c抑制剂的3-酰氨基-吡咯并[3,4-c]吡唑-5(1h,4h,6h)甲醛衍生物 |
| US7981904B2 (en) | 2008-03-20 | 2011-07-19 | Takeda Pharmaceutical Company Limited | Acetyl CoA carboxylase inhibitors |
| JP5435592B2 (ja) | 2008-05-28 | 2014-03-05 | ファイザー・インク | ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤 |
| CA2724603A1 (en) | 2008-05-28 | 2009-12-03 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| AU2009266730B2 (en) | 2008-07-04 | 2013-07-18 | Msd K.K. | Novel spirochromanone carboxylic acids |
| WO2010008521A1 (en) | 2008-07-14 | 2010-01-21 | Cropsolution, Inc. | Modulators of acetyl-coenzyme a carboxylase and methods of use thereof |
| ES2444543T3 (es) * | 2009-11-10 | 2014-02-25 | Pfizer Inc | Inhibidores de la N1-pirazoloespirocetona acetil-CoA carboxilasa |
| EP2499140A1 (en) * | 2009-11-10 | 2012-09-19 | Pfizer Inc. | N2-pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| EP2621493B1 (en) * | 2010-09-30 | 2016-08-17 | Pfizer Inc | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS |
| US20160034775A1 (en) | 2014-08-02 | 2016-02-04 | General Vault, LLC | Methods and apparatus for bounded image data analysis and notification mechanism |
-
2011
- 2011-09-20 EP EP11768163.5A patent/EP2621493B1/en active Active
- 2011-09-20 LT LTEP11768163.5T patent/LT2621493T/lt unknown
- 2011-09-20 PT PT117681635T patent/PT2621493T/pt unknown
- 2011-09-20 HR HRP20161178TT patent/HRP20161178T1/hr unknown
- 2011-09-20 PL PL11768163T patent/PL2621493T3/pl unknown
- 2011-09-20 DK DK11768163.5T patent/DK2621493T3/en active
- 2011-09-20 HU HUE11768163A patent/HUE031616T2/hu unknown
- 2011-09-20 ES ES11768163.5T patent/ES2602111T3/es active Active
- 2011-09-20 WO PCT/IB2011/054119 patent/WO2012042433A1/en not_active Ceased
- 2011-09-20 JP JP2013530829A patent/JP5824055B2/ja active Active
- 2011-09-20 RS RS20160845A patent/RS55224B1/sr unknown
- 2011-09-20 US US13/876,211 patent/US8859577B2/en active Active
- 2011-09-20 SI SI201130951A patent/SI2621493T1/sl unknown
- 2011-09-20 CA CA2811033A patent/CA2811033C/en active Active
-
2014
- 2014-09-19 US US14/491,016 patent/US9145416B2/en active Active
-
2015
- 2015-09-11 US US14/851,572 patent/US20150376185A1/en not_active Abandoned
-
2016
- 2016-08-15 US US15/236,635 patent/US9908883B2/en active Active
- 2016-09-13 CY CY20161100905T patent/CY1118016T1/el unknown
-
2018
- 2018-01-30 US US15/883,109 patent/US10294225B2/en active Active
-
2019
- 2019-04-01 US US16/371,896 patent/US10822335B2/en active Active
-
2020
- 2020-09-28 US US17/034,295 patent/US11673890B2/en active Active
-
2023
- 2023-05-03 US US18/311,715 patent/US20230322777A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013540119A5 (cg-RX-API-DMAC7.html) | ||
| HRP20161178T1 (hr) | N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE | |
| HRP20140025T1 (hr) | N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE | |
| US20230227471A1 (en) | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway | |
| JP2010515734A5 (cg-RX-API-DMAC7.html) | ||
| EP3630770B1 (en) | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors | |
| US7173034B2 (en) | Respiratory syncytial virus replication inhibitors | |
| AU2020276802A1 (en) | Inhibitor containing bicyclic derivative, preparation method therefor and use thereof | |
| RU2016140338A (ru) | Азаспиро производные в качестве антагонистов trpm8 | |
| JP2021501220A5 (cg-RX-API-DMAC7.html) | ||
| ES2271221T3 (es) | Derivados imidazo-pirimidina como ligandos para receptores gaba. | |
| RU2018138050A (ru) | Производные тиазолопиридина как агонисты gpr119 | |
| US20100222325A1 (en) | Inhibitors of Bruton's Tyrosine Kinase | |
| HRP20160539T1 (hr) | Antagonisti trpv4 | |
| JP2012525395A5 (cg-RX-API-DMAC7.html) | ||
| RU2017106742A (ru) | Комбинированная терапия для лечения парамиксовируса | |
| JP2022507724A (ja) | 抗ウイルス剤としての官能化複素環 | |
| JP2016531874A5 (cg-RX-API-DMAC7.html) | ||
| JP2013531684A5 (cg-RX-API-DMAC7.html) | ||
| RU2012136643A (ru) | [5,6]- гетероциклическое соединение | |
| JP2006519205A (ja) | ピラゾロピリジン誘導体 | |
| JP2016507551A5 (cg-RX-API-DMAC7.html) | ||
| US20130150360A1 (en) | Inhibitors of bruton's tyrosine kinase | |
| JP2013542204A5 (cg-RX-API-DMAC7.html) | ||
| JP2012515789A5 (cg-RX-API-DMAC7.html) |